In the present work, we did not evaluate the therapeutic window of Phα1β and ω-conotoxin MVIIA. However, in a previous study, native and recombinant Phα1β spinally administered has analgesic action in rodent models of chronic and acute pain, with a therapeutic window four times larger than ω-conotoxin MVIIA (Souza et al.,

2008). It is noteworthy to mention that we previously showed that Phα1β not Trametinib only prevented phase-2 behavior when administered before formalin injection, but it also reversed phase-2 behavior when it was administered after formalin injection (Souza et al., 2008). In the present study, we confirmed that the administration of Phα1β, before or after the plantar incision, was able to reduce the induced-pain with a long-lasting antinociceptive effect than morphine or ω-conotoxin MVIIA. These observations raise the possibility that Phα1β might be useful for the management of surgical pain by a preemptive effect as well as

a pain therapeutic agent on the postoperative period. The duration of the antiallodynic effect of preemptive and post-incision administration of Phα1β (200 pmol/site) was longer than with 100 pmol/site. However, we did not observe a dose dependent response on the maximum effect with selleck chemical the different doses of the toxin. In contrast, ω-conotoxin MVIIA (10 pmol/site) reduced mechanical allodynia that was twice higher than the dose of 1.0 pmol/site with a similar duration of action. The differences observed

with the toxins may be related to differences on their pharmacokinetics. Moreover, we could speculate that with high concentrations of Phα1β (200 pmol/site) there is a reduction in the specificity of the toxin and thus it can bind to other ions channels involved in nociception (Vieira et al., 2005). Therefore, further investigations are necessary to investigate these points. It has been shown that intrathecal ziconotide induced clinical and behavioral CNS effects such as tremoring, shaking behavior, ataxia and hyperreactivity in rats, dogs and monkeys (Skov et al., 2007). Clinical studies also reported several Avelestat (AZD9668) side effects in humans as abnormal gait, ataxia, hypertonia and tremor (Skov et al., 2007). In the present study, a number of pre-clinical tests have been conducted to establish the cardiovascular profile, neurological global behavior and pro-inflammatory potential of Phα1β by comparing with morphine and ω-conotoxin MVIIA. One of the main adverse effects caused by intrathecal administration of ziconotide in humans is hypotension (Penn and Paice, 2000). In fact, the i.v. administration of MVIIA in rabbits also reduced the blood pressure ( Wright et al., 2000). However, in the present study, we found that intrathecal injection of Phα1β, morphine and ω-conotoxin MVIIA did not change the MAP 0.5 and 3 h after the administration.